Literature DB >> 30992296

All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013).

Konstantinos Tselios1, Dafna D Gladman1,2, Barry J Sheane3, Jiandong Su1, Murray Urowitz4.   

Abstract

BACKGROUND: Survival in systemic lupus erythematosus (SLE) has improved substantially in the last 50 years. The aim of the present study was to assess the evolution of the all-cause, cause-specific and age-specific standardised mortality ratios (SMRs) of patients with lupus in Ontario, Canada. PATIENTS AND METHODS: Between 1971 and 2013, 1732 patients were followed in the Toronto Lupus Clinic. Causes of death were retrieved from death certificates, autopsy reports, hospital records or the records of the family physicians. They were categorised as atherosclerotic, infectious, malignancy, active lupus and others. For the calculation of the SMR (indirect standardisation method), data from the general population of Ontario, Canada were used (Statistics Canada).
RESULTS: Two hundred and forty-nine patients (205 women) died (infections 24.5%, atherosclerosis 15.7%, active lupus 13.3%, malignancy 9.6%); mean age was 53.2±16.6 years and mean disease duration 15.2±11.7 years. The all-cause SMR was substantially decreased from the 1970s (13.5, 95% CI 8.6 to 18.5) to recent years (2.2, 95% CI 1.4 to 3.1). Similar trends were observed for atherosclerosis, infections and malignancies over time. The all-cause age-specific SMR was particularly high in younger (19-39 years old) patients (SMR=12.4, 95% CI 9.7 to 15.1) as compared with individuals older than 40 years (SMR=3.1, 95% CI 2.6 to 3.6). The cause-specific SMR was also higher in younger patients, particularly for infections and malignancies.
CONCLUSIONS: The all-cause and cause-specific SMR significantly decreased over time, likely reflecting the advances in the management of SLE and certain comorbidities. The all-cause and cause-specific SMR was particularly high for younger patients (<40 years old). © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  causes of death; standardized mortality ratio; systemic lupus erythematosus

Year:  2019        PMID: 30992296     DOI: 10.1136/annrheumdis-2018-214802

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  26 in total

1.  In-hospital mortality reduction in systemic lupus erythematosus over 2 decades varied by patient sex and age.

Authors:  Jasvinder A Singh
Journal:  Clin Rheumatol       Date:  2021-01-04       Impact factor: 2.980

2.  Low dosage use of cyclophosphamide improves the survival of patients with systemic lupus erythematosus.

Authors:  Yoosuf Ali Ashraf Muhammad Hussenbocus; Ziyi Jin; Wenyou Pan; Lin Liu; Min Wu; Huaixia Hu; Xiang Ding; Hua Wei; Yaohong Zou; Xian Qian; Meimei Wang; Jian Wu; Juan Tao; Jun Tan; Zhanyun Da; Miaojia Zhang; Jing Li; Xuebing Feng; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2022-03-01       Impact factor: 2.980

3.  2019-EULAR/ACR classification criteria domains at diagnosis: predictive factors of long-term damage in systemic lupus erythematosus.

Authors:  Carlos E Insfrán; Nadia E Aikawa; Clovis A Silva; Eloisa Bonfa; Sandra G Pasoto; Dilson M N Filho; Francisco F C Formiga; Ana C Pitta; Eduardo F Borba; Carolina T Ribeiro
Journal:  Clin Rheumatol       Date:  2021-11-16       Impact factor: 2.980

Review 4.  Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus.

Authors:  Christopher B Oliveira; Mariana J Kaplan
Journal:  Semin Immunopathol       Date:  2022-03-30       Impact factor: 11.759

5.  All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study.

Authors:  Bahar Moghaddam; Shelby Marozoff; Lingyi Li; Eric C Sayre; J Antonio Aviña- Zubieta
Journal:  Rheumatology (Oxford)       Date:  2021-12-24       Impact factor: 7.580

6.  Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease.

Authors:  Dionysis S Nikolopoulos; Myrto Kostopoulou; Dimitrios T Boumpas; Antonis Fanouriakis; Antigoni Pieta; Sofia Flouda; Katerina Chavatza; Aggelos Banos; John Boletis; Pelagia Katsimbri
Journal:  Lupus Sci Med       Date:  2020-06

7.  Racial Disparities in Mortality Associated with Systemic Lupus Erythematosus - Fulton and DeKalb Counties, Georgia, 2002-2016.

Authors:  S Sam Lim; Charles G Helmick; Gaobin Bao; Jennifer Hootman; Rana Bayakly; Caroline Gordon; Cristina Drenkard
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-05-10       Impact factor: 17.586

8.  Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis.

Authors:  Arthur Petitdemange; Julien Blaess; Jean Sibilia; Renaud Felten; Laurent Arnaud
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-12-16       Impact factor: 5.346

9.  Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus.

Authors:  Melinda Kedves; Fruzsina Kósa; Péter Kunovszki; Péter Takács; Melinda Zsuzsanna Szabó; Chetan Karyekar; Jennifer H Lofland; György Nagy
Journal:  Rheumatology (Oxford)       Date:  2020-11-01       Impact factor: 7.580

10.  Outcomes of membranous and proliferative lupus nephritis - analysis of a single-centre cohort with more than 30 years of follow-up.

Authors:  Filipa Farinha; Ruth J Pepper; Daniel G Oliveira; Thomas McDonnell; David A Isenberg; Anisur Rahman
Journal:  Rheumatology (Oxford)       Date:  2020-11-01       Impact factor: 7.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.